CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.
Jia Liu, Jianwei Yang, Yuping Sun...
https://pubmed.ncbi.nlm.nih.gov/40670773/Actively Recruiting
Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2026-05-04
470
Participants Needed
39
Research Sites
26 weeks
Total Duration
Researchers are evaluating IBI343 in people with locally advanced unresectable or metastatic solid tumors in a Phase IaIb, multicenter, open-label, first-in-human study. The trial aims to assess the safety, tolerability, how the drug moves through the body, and its effectiveness. The study includes participants from China, Australia, and the US and involves various stages to find the best dose and combination therapies. IBI343 is given intravenously and the study is divided into multiple parts. Phase Ia includes dose escalation, dose expansion, and dose optimization for monotherapy, with doses adjusted to balance benefits and risks. Phase Ib includes combination therapy with chemotherapy drugs like FOLFIRINOX or mFOLFOX, given every two to three weeks, with randomized groups to determine the optimal dose and safety. Participants will have regular visits for treatment and monitoring, including physical exams, laboratory tests, and imaging to measure tumor response using RECIST criteria. Safety is closely followed through adverse event tracking up to two years, along with assessments of drug levels in the body and immune response. The study also evaluates how tumor markers relate to treatment response, with total participation lasting up to two years.
CONDITIONS
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
S
Suhua Dong
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Innovent Biologics (Suzhou) Co. Ltd.
Lead Sponsor
Fortvita Biologics (USA)Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | IBI343 antibody-drug conjugate | FOLFIRINOX or modified FOLFIRINOX chemotherapy | Modified FOLFOX (mFOLFOX) chemotherapy |
|---|---|---|---|
| What it is | An investigational antibody-drug conjugate targeting CLDN18.2, administered intravenously; designed to deliver cytotoxic treatment directly to tumor cells expressing CLDN18.2. | A combination chemotherapy regimen including fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or a modified variant (mFOLFIRINOX), administered intravenously, and widely used in advanced gastrointestinal cancers. | A modified FOLFOX regimen consisting of fluorouracil, leucovorin, and oxaliplatin, administered intravenously, established as a standard therapy in advanced gastrointestinal tumors. |
| Primary use in this study | Being studied to determine the safety, tolerability, and initial anti-tumor activity of IBI343 in patients with CLDN18.2-positive advanced solid tumors. | Serves as an active comparator within the randomized trial arms, representing current guideline-based chemotherapy for advanced disease. | Acts as a comparator chemotherapy arm offering an alternative standard regimen for advanced, unresectable or metastatic solid tumors expressing CLDN18.2. |
| How it is given | Administered as an intravenous infusion on Day 1 of every 21-day cycle (every 3 weeks), per protocol. | Given as an intravenous infusion on Days 1 to 3 every 2 weeks (FOLFIRINOX/mFOLFIRINOX), consistent with standard clinical protocols. | Administered intravenously on Days 1 to 3 of each cycle every 2 weeks, following established dosing practice for mFOLFOX. |
| Evidence status | Efficacy and safety are currently under investigation. Phase 1 preliminary results for advanced gastric/GEJ adenocarcinoma suggest initial anti-tumor activity and an acceptable safety profile, with further results awaited. | Efficacy and risks are well-established in multiple phase 3 randomized controlled trials and reflected in clinical guidelines; proven survival benefit in advanced gastrointestinal malignancies. | Established in clinical practice, with survival benefit demonstrated in phase 3 randomized trials in advanced gastrointestinal cancers. |
| Important limitations | Efficacy and safety remain investigational as phase 1 data are early and focused on dose-escalation; benefit-risk profile in larger and more diverse populations is not yet established. | Associated with significant toxicity including neutropenia, gastrointestinal effects, and neuropathy; not all patients are candidates due to performance status or comorbidities. | Toxicity, especially neuropathy, and need for careful dose adjustment may limit mFOLFOX in some patients; efficacy may be lower compared to FOLFIRINOX in particular tumor types. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Repeated 21-day or 14-day cycles until disease progression or discontinuation
Participants receive IBI343 and may receive combination chemotherapy regimens intravenously on specific schedules as part of treatment for locally advanced unresectable or metastatic solid tumors.
IV administration on Day 1 of every 21-day cycle or every 2 weeks depending on regimen
Duration - Up to 2 years after last treatment
Participants are monitored for adverse events, treatment response, and survival outcomes after treatment ends.
Visits according to study schedule for safety and efficacy assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jia Liu, Jianwei Yang, Yuping Sun...
https://pubmed.ncbi.nlm.nih.gov/40670773/Innovent Biologics (Suzhou) Co. Ltd.
Lead Sponsor
Fortvita Biologics (USA)Inc.
Collaborating Sponsor